Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
member
Seven Oaks Capital Corp.is pleased to announce that it has entered into a binding letter agreement dated January 29, 2023 (the "Definitive Agreement") with Rimon Hedge Funds Ltd.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.